Investigational drug · Phase 3
Nucresiran
Also called: ALN-TTRSC04
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Transthyretin Amyloidosis With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Nucresiran"
First trial start
2025
Jul 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nucresiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Transthyretin Amyloidosis With Cardiomyopathy
- Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
- hATTR-PN
Approved drugs for the same conditions: Transthyretin amyloidosis · Cardiovascular and metabolic · Neurology · Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nucresiran" as an intervention, largest first.
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07052903 · 2,250 participants (planned) · Start Jul 2, 2025 · Primary completion May 28, 2030
Drug: Nucresiran; Sterile Normal Saline (0.9% NaCl) · For: Transthyretin Amyloidosis With Cardiomyopathy
Sites: La Jolla, California; Laguna Hills, California; Stanford, California · 267 sites in all
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07223203 · 125 participants (planned) · Start Feb 3, 2026 · Primary completion Dec 27, 2027
Drug: Nucresiran; Vutrisiran · For: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
Sites: Aurora, Colorado; Chicago, Illinois; Baltimore, Maryland · 61 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Alnylam Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.